MD3361F1 - Method of treating the infantile cerebral paralysis - Google Patents

Method of treating the infantile cerebral paralysis

Info

Publication number
MD3361F1
MD3361F1 MDA20060253A MD20060253A MD3361F1 MD 3361 F1 MD3361 F1 MD 3361F1 MD A20060253 A MDA20060253 A MD A20060253A MD 20060253 A MD20060253 A MD 20060253A MD 3361 F1 MD3361 F1 MD 3361F1
Authority
MD
Moldova
Prior art keywords
region
compositum
biologically active
active points
weeks
Prior art date
Application number
MDA20060253A
Other languages
Romanian (ro)
Other versions
MD3361G2 (en
Inventor
Svetlana Hadjiu
Original Assignee
Svetlana Hadjiu
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Svetlana Hadjiu filed Critical Svetlana Hadjiu
Priority to MDA20060253A priority Critical patent/MD3361G2/en
Publication of MD3361F1 publication Critical patent/MD3361F1/en
Publication of MD3361G2 publication Critical patent/MD3361G2/en

Links

Landscapes

  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Inventia se refera la medicina, in special la neurologie, pediatrie, reflexoterapie, si poate fi utilizata pentru ameliorarea calitatii tratamentului bolnavilor cu forme spastice si spastico-hiperchinetice ale paraliziei cerebrale la copii. Metoda,conform inventiei, consta in aceea ca in decurs de 1…2 luni se administreaza preparatele Lymphomyosot, Berberis-Homaccord, Nux vomica-Homaccord cate4…7 picaturi de 3 ori pe zi per os, Coenzyme Compositum cate 0,9…1,8 ml de 2 ori pe saptamana intramuscular, Ubichinon Compositum cate 0,9…1,8 ml de 2 ori pe saptamana intramuscular, Nevroheeli cate 1 pastila de 3 ori pe zi, Spascupreel cate 1 supozitor pe noapte. Incepand cu a treia saptamana de tratament, se administreaza Cerebrum Compositum,Placenta Compositum, Arteria Heel cate 1,0…2,5 mlde 2 ori pe saptamana subcutanat in regiunea punctelor biologic active G14, P7, MC6, TR6, TR5, E36,VB34, RP6, E36, IG3, V62, C5, VB39, VB20, V23, totodata fiecare preparat medicamentos se administreaza in regiunea a 5 puncte biologic active, repetand alternarea lor timp de 3 saptamani. Apoi, in urmatoarele 3 saptamani, aceste preparate in aceeasiconsecutivitate se administreaza in regiunea punctelor biologic active C3, V62, IG3, T14, V10, 13, VB20, 21, T3, 5, V23, 28, 31, 34, iar in urmatoarele 3…4 saptamani in regiunea punctelor biologic active IG12, 15, G14-15, TR3-10, G14, 5, 6, 10, 11,MC5, 8, IG11, P10, VB20, 21, 30, 31, 34, V11, 15, 57, 60, E32, 41, IG3, 9, 14, T4, 14, 20, P5, 7, MC5, 6, GI10.The invention relates to medicine, in particular to neurology, pediatrics, reflexology, and may be used to improve the quality of treatment of patients with spastic and hyper-kinetic spastic forms of cerebral palsy in children. The method, according to the invention, consists in the fact that within 1… 2 months the preparations of Lymphomyosot, Berberis-Homaccord, Nux vomica-Homaccord are administered4… 7 drops 3 times daily per bone, Coenzyme Compositum each 0.9… 1, 8 ml 2 times per week intramuscularly, Ubichinon Compositum each 0.9 ... 1.8 ml 2 times per week intramuscularly, Nevroheels each 1 pill 3 times daily, Spascupreel each 1 suppository per night. Starting with the third week of treatment, Cerebrum Compositum, Placenta Compositum, Heel Artery are administered 1.0 ... 2.5 billion 2 times per week subcutaneously in the region of biologically active points G14, P7, MC6, TR6, TR5, E36, VB34 , RP6, E36, IG3, V62, C5, VB39, VB20, V23, at the same time each drug preparation is administered in the region of 5 biologically active points, repeating their alternation for 3 weeks. Then, in the next 3 weeks, these preparations in the same sequence are administered in the region of biologically active points C3, V62, IG3, T14, V10, 13, VB20, 21, T3, 5, V23, 28, 31, 34, and in the next 3 … 4 weeks in the region of biologically active points IG12, 15, G14-15, TR3-10, G14, 5, 6, 10, 11, MC5, 8, IG11, P10, VB20, 21, 30, 31, 34, V11, 15, 57, 60, E32, 41, IG3, 9, 14, T4, 14, 20, P5, 7, MC5, 6, GI10.

MDA20060253A 2006-10-27 2006-10-27 Method of treating the infantile cerebral paralysis MD3361G2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
MDA20060253A MD3361G2 (en) 2006-10-27 2006-10-27 Method of treating the infantile cerebral paralysis

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
MDA20060253A MD3361G2 (en) 2006-10-27 2006-10-27 Method of treating the infantile cerebral paralysis

Publications (2)

Publication Number Publication Date
MD3361F1 true MD3361F1 (en) 2007-07-31
MD3361G2 MD3361G2 (en) 2008-02-29

Family

ID=38331522

Family Applications (1)

Application Number Title Priority Date Filing Date
MDA20060253A MD3361G2 (en) 2006-10-27 2006-10-27 Method of treating the infantile cerebral paralysis

Country Status (1)

Country Link
MD (1) MD3361G2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2485983C2 (en) * 2011-09-16 2013-06-27 Максимильян Григорьевич Кравчик Method for recovering sensor-motor function of central nervous system and peripheral nerves

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2168976C2 (en) * 1999-03-01 2001-06-20 Новокузнецкий государственный институт усовершенствования врачей Method of treating babies with cerebral paralysis

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2485983C2 (en) * 2011-09-16 2013-06-27 Максимильян Григорьевич Кравчик Method for recovering sensor-motor function of central nervous system and peripheral nerves

Also Published As

Publication number Publication date
MD3361G2 (en) 2008-02-29

Similar Documents

Publication Publication Date Title
Vinayak et al. Adverse affects of drugs on saliva and salivary glands
Al-Aizari et al. Oral manifestations of Parry-Romberg syndrome: a review of literature
Karasek et al. The future of melatonin as a therapeutic agent
NZ767378A (en) Dosage forms and methods for enantiomerically enriched or pure bupropion
MD3361F1 (en) Method of treating the infantile cerebral paralysis
MD3359F1 (en) Method of conservative treatment of diskal hernia
Bech et al. Dapsone for the treatment of chronic IgA vasculitis (Henoch-Schonlein)
ATE366581T1 (en) APOPTOTIC BODY FOR USE IN THE TREATMENT OF NEURODEGENERATIVE AND OTHER NERVOUS DISEASES
MD3803F1 (en) Method of treating hyperkinesia of children
MD3906G2 (en) Method for treating the neurotic enuresis to children
MX2023008804A (en) Liquid formulation of protein and methods of preparing the same.
CN100402039C (en) Hair growth promoting liquid
CN105232577A (en) Technology for growing hair by using adipose-derived stem cell factors
MD3927F1 (en) Method for treating the facial paralysis
JP2004189676A (en) External preparation for ameliorating damaged skin
Solomennyi STUDY OF THE QUALITY COMPOSITION OF MODERN WOUND-HEALING AGENTS BASED ON DECAMETOXIN AND METHYLURACIL
Achard Is the WHO weight for age chart appropriate for infants of the developing world?
Rahill Mammary gland changes during chlorpromazine therapy
MD3885F1 (en) Method for polyparasitosis complex treatment to cattle
CN101919889A (en) External angelica pus-eliminating ointment
ATE160091T1 (en) BOXWOOD PREPARATION FOR TREATMENT OF HIV INFECTION
Aparna et al. An effective management of collapse compression fracture through Panchakarma-A Case Study
KR20240086411A (en) Medium composition for inhibiting cytotoxicity induced by degenerative neuropathogenic factors
Moratschek et al. Treatment Considerations During Lactation for Adolescents with Bipolar Disorder
Boots et al. DEGENERATIVE JOINT DISEASE OF THE HIP: RELIEF OF SYMPTOMS FOLLOWING CORTISONE THERAPY

Legal Events

Date Code Title Description
FG4A Patent for invention issued
KA4A Patent for invention lapsed due to non-payment of fees (with right of restoration)
MM4A Patent for invention definitely lapsed due to non-payment of fees